Corrigendum: Myelodysplastic syndrome/acute myeloid leukemia following the use of poly-ADP ribose polymerase inhibitors: A real-world analysis of postmarketing surveillance data.

Front Pharmacol

Published: August 2022

[This corrects the article DOI: 10.3389/fphar.2022.912256.].

Download full-text PDF	Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9403888	PMC
http://dx.doi.org/10.3389/fphar.2022.990048	DOI Listing

Publication Analysis

corrigendum myelodysplastic

myelodysplastic syndrome/acute

syndrome/acute myeloid

myeloid leukemia

leukemia poly-adp

poly-adp ribose

ribose polymerase

polymerase inhibitors

inhibitors real-world

real-world analysis

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!